Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2018 - 2020)

Historic Non-Current Deferred Tax Liability for Zevra Therapeutics (ZVRA) over the last 5 years, with Q4 2020 value amounting to $476000.0.

  • Zevra Therapeutics' Non-Current Deferred Tax Liability fell 1185.19% to $476000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $476000.0, marking a year-over-year decrease of 1185.19%. This contributed to the annual value of $476000.0 for FY2020, which is 1185.19% down from last year.
  • Per Zevra Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $476000.0 for Q4 2020, which was down 1185.19% from $540000.0 recorded in Q4 2019.
  • Zevra Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $540000.0 during Q4 2019, with a 5-year trough of $171000.0 in Q4 2018.
  • Its 3-year average for Non-Current Deferred Tax Liability is $395666.7, with a median of $476000.0 in 2020.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 21578.95% in 2019, then crashed by 1185.19% in 2020.
  • Zevra Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $171000.0 in 2018, then skyrocketed by 215.79% to $540000.0 in 2019, then fell by 11.85% to $476000.0 in 2020.
  • Its last three reported values are $476000.0 in Q4 2020, $540000.0 for Q4 2019, and $171000.0 during Q4 2018.